评估 COVID-19 患者的噬血细胞性淋巴组织细胞增生症 H 评分。
Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.
机构信息
Department for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom.
Department of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
出版信息
Clin Infect Dis. 2021 Nov 2;73(9):e3110-e3112. doi: 10.1093/cid/ciaa1463.
Abstract
The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.
摘要
中度至重度 2019 年冠状病毒病（COVID-19）的临床表现与继发性噬血细胞性淋巴组织细胞增生症（HLH）在临床上和基于分子炎症反应方面具有相似性。我们没有发现证据支持使用专为 HLH 设计的风险评分方法对 COVID-19 患者进行风险分层的效用。
相似文献
1
Assessment of the Hemophagocytic Lymphohistiocytosis HScore in Patients With Coronavirus Disease 2019.评估 COVID-19 患者的噬血细胞性淋巴组织细胞增生症 H 评分。
Clin Infect Dis. 2021 Nov 2;73(9):e3110-e3112. doi: 10.1093/cid/ciaa1463.
2
Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.噬血细胞性淋巴组织细胞增生症：COVID-19 大流行引发的综述。
Rheumatol Int. 2021 Jan;41(1):7-18. doi: 10.1007/s00296-020-04636-y. Epub 2020 Jun 25.
3
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.COVID-19 相关细胞因子风暴综合征与诊断原则：一个古老而崭新的议题。
Emerg Microbes Infect. 2021 Dec;10(1):266-276. doi: 10.1080/22221751.2021.1884503.
4
COVID-19 Associated Hemophagocytic Lymphohistiocytosis and Coagulopathy: Targeting the Duumvirate.COVID-19 相关噬血细胞性淋巴组织细胞增生症和凝血障碍：针对双联体。
Indian Pediatr. 2020 Sep 15;57(9):827-833. doi: 10.1007/s13312-020-1962-z. Epub 2020 Jun 24.
5
Do COVID-19 Infections Result in a Different Form of Secondary Hemophagocytic Lymphohistiocytosis.新冠病毒感染是否导致不同形式的继发性噬血细胞性淋巴组织细胞增生症？
Int J Mol Sci. 2021 Mar 15;22(6):2967. doi: 10.3390/ijms22062967.
6
[Secondary hemophagocytic lymphohistiocytosis and cytokine release syndrome in COVID-19, the same or different entities?].[新型冠状病毒肺炎中的继发性噬血细胞性淋巴组织细胞增生症和细胞因子释放综合征，是同一实体还是不同实体？]
Rev Chilena Infectol. 2021 Apr;38(2):271-278. doi: 10.4067/S0716-10182021000200271.
7
Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients.严重 2019 冠状病毒病成年患者发生继发性噬血细胞性淋巴组织细胞增生症的危险因素。
BMC Infect Dis. 2021 Apr 29;21(1):398. doi: 10.1186/s12879-021-06094-8.
8
SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis.严重急性呼吸综合征冠状病毒 2 感染相关性噬血细胞性淋巴组织细胞增生症。
Am J Clin Pathol. 2020 Sep 8;154(4):466-474. doi: 10.1093/ajcp/aqaa124.
9
Hemophagocytic syndrome secondary to SARS-Cov-2 infection: a case report.继发于 SARS-CoV-2 感染的噬血细胞综合征：一例报告。
BMC Infect Dis. 2021 Aug 13;21(1):811. doi: 10.1186/s12879-021-06532-7.
10
Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?噬血细胞性淋巴组织细胞增生症是否为重症 COVID-19 病例的核心问题？
BMC Med. 2020 Jul 15;18(1):214. doi: 10.1186/s12916-020-01682-y.
引用本文的文献
1
The pathophysiology of hemophagocytic lympho-histiocytosis (HLH) syndrome and insights from animal models.噬血细胞性淋巴组织细胞增生症（HLH）综合征的病理生理学及来自动物模型的见解。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf036.
2
Secondary Hemophagocytic Lymphohistiocytosis in severe COVID-19 - a retrospective cohort study.重症新型冠状病毒肺炎中的继发性噬血细胞性淋巴组织细胞增生症——一项回顾性队列研究
Sci Rep. 2025 Feb 20;15(1):6137. doi: 10.1038/s41598-025-90766-x.
3
Severe COVID-19-associated hyperinflammatory syndrome versus classic hemophagocytic lymphohistiocytosis: similarities, differences, and the way forward.严重 COVID-19 相关的过度炎症综合征与经典噬血细胞性淋巴组织细胞增生症：相似之处、不同之处及未来方向。
J Investig Med. 2023 Mar;71(3):244-253. doi: 10.1177/10815589221140596.
4
Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review.深入探讨 COVID-19 的免疫病理生理学机制：综述
Front Immunol. 2022 Mar 24;13:835104. doi: 10.3389/fimmu.2022.835104. eCollection 2022.
5
Assessment of the HScore as a predictor of disease outcome in patients with COVID-19.评估 H 评分在 COVID-19 患者疾病结局预测中的作用。
BMC Pulm Med. 2021 Oct 29;21(1):338. doi: 10.1186/s12890-021-01706-0.
6
The Effects of COVID-19 on the Placenta During Pregnancy.COVID-19 对妊娠期胎盘的影响。
Front Immunol. 2021 Sep 15;12:743022. doi: 10.3389/fimmu.2021.743022. eCollection 2021.
7
Association of HScore Parameters with Severe COVID-19: A Systematic Review and Meta-Analysis.HScore参数与重症新型冠状病毒肺炎的关联：一项系统评价与Meta分析
Iran J Med Sci. 2021 Sep;46(5):322-338. doi: 10.30476/IJMS.2021.88404.1910.
8
Usefulness of Easy-to-Use Risk Scoring Systems Rated in the Emergency Department to Predict Major Adverse Outcomes in Hospitalized COVID-19 Patients.急诊科使用的简易风险评分系统对预测住院COVID-19患者主要不良结局的有效性。
J Clin Med. 2021 Aug 18;10(16):3657. doi: 10.3390/jcm10163657.
9
Abnormality in the NK-cell population is prolonged in severe COVID-19 patients.在重症 COVID-19 患者中，NK 细胞群体的异常持续时间延长。
J Allergy Clin Immunol. 2021 Oct;148(4):996-1006.e18. doi: 10.1016/j.jaci.2021.07.022. Epub 2021 Jul 31.
10
Infection-induced inflammation from specific inborn errors of immunity to COVID-19.COVID-19 相关特定先天性免疫缺陷引起的感染性炎症。
FEBS J. 2021 Sep;288(17):5021-5041. doi: 10.1111/febs.15961. Epub 2021 May 20.
Zotero 插件